Cita APA

L, L., JM, P., S, B., J, B., JÁ, G., EF, V., . . . A, L. (2025). Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation.

Citación estilo Chicago

L, Lema, et al. Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer With a Germline BRCA Mutation. 2025.

Cita MLA

L, Lema, et al. Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer With a Germline BRCA Mutation. 2025.